The virulence domain of Shigella IcsA contains a subregion with specific host cell adhesion function
Authors:
Jilong Qin aff001; Matthew Thomas Doyle aff001; Elizabeth Ngoc Hoa Tran aff001; Renato Morona aff001
Authors place of work:
School of Biological Sciences, Department of Molecular & Biomedical Sciences, Research Centre for Infectious Diseases, University of Adelaide, Adelaide, Australia
aff001
Published in the journal:
PLoS ONE 15(1)
Category:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0227425
Summary
Shigella species cause bacillary dysentery, especially among young individuals. Shigellae target the human colon for invasion; however, the initial adhesion mechanism is poorly understood. The Shigella surface protein IcsA, in addition to its role in actin-based motility, acts as a host cell adhesin through unknown mechanism(s). Here we confirmed the role of IcsA in cell adhesion and defined the region required for IcsA adhesin activity. Purified IcsA passenger domain was able block S. flexneri adherence and was also used as a molecular probe that recognised multiple components from host cells. The region within IcsA’s functional passenger domain (aa 138–148) was identified by mutagenesis. Upon the deletion of this region, the purified IcsAΔ138–148 was found to no longer block S. flexneri adherence and had reduced ability to interact with host molecules. Furthermore, S. flexneri expressing IcsAΔ138–148 was found to be significantly defective in both cell adherence and invasion. Taken together, our data identify an adherence region within the IcsA functional domain and provides useful information for designing therapeutics for Shigella infection.
Keywords:
HeLa cells – Adhesins – Host cells – Nitrocellulose – Shigella – Centrifugation – Shigella flexneri – Shigellosis
Introduction
Shigellae are Gram-negative bacteria that cause severe bloody diarrhoea in humans [1] and rhesus monkeys [2]. Shigellosis is life threating to children under 4 years of age [3] and is a growing health problem in developed countries due to decreased susceptibility to antibiotics [4]. Shigella spp. are primate specific pathogens that target the colon [1, 5] and it has been demonstrated in the rabbit ligated ileum model [6], and in vitro colonoids [7], that Shigella can be taken up by M cells. However, Shigella has been reported to target the human colonic crypts where M cells were not present [8], strongly indicating that an alternative route of entry exists. Indeed, the mechanisms by which Shigella species initially adhere to host cells, a prerequisite for subsequent invasion and establishing infection, remains poorly understood.
A role in host cell adhesion has been recently revealed for the essential surface displayed virulence factor IcsA [9]. IcsA is 100% conserved in Shigella species and is a member of the secreted autotransporter (AT) superfamily. IcsA contains a signal sequence (aa 1–52) at its N-terminus for secretion across the inner membrane; a passenger domain (aa 53–740) which confers its function; a β-barrel domain (aa 813–1102) which is responsible for passenger domain translocation across the outer membrane; and an unstructured linker region (aa 741–812) that connects the passenger with the β-barrel. IcsA also belongs to the AIDA subfamily with members that are well characterised adhesins, such as AIDA-I and Ag43, both of which are known to have β-helix passenger structures [10–12]. The IcsA passenger also possesses these β-helix structures [13–16]. IcsA has been well studied with respect to its function in actin based motility (ABM) [17, 18], where polarly distributed IcsA recruits host N-WASP protein [19–21], resulting in the subsequent polymerisation of host cell actin at one pole of the bacterium to facilitate bacterial inter- and intracellular motility [22]. Recently, IcsA has been found contributing to S. flexneri biofilm formation in the presence of bile salt deoxycholate (DOC) by promoting cell-to-cell contact and aggregative bacterial growth [23]. Besides ABM and biofilm formation, however, knockouts of the type 3 secretion tip complex proteins IpaD or IpaB in Shigella flexneri result in polar adhesion to host cells in an IcsA-dependent manner [9]. IcsA was also found to contribute to DOC induced hyper-adherence, and expressing IcsA in E. coli promotes adherence to host cells, confirming that IcsA is sufficient to promote bacterial adherence [9]. While IcsA’s expression level and cellular distribution is not altered in the hyper-adherent Shigella compared to the wild type strain, data suggest that the conformation of IcsA is different in hyper-adherent strains [9].
In this study, the direct role of IcsA in Shigella-host-cell adherence was demonstrated via adherence inhibition with purified IcsA passenger domain, and adherence blocking with anti-IcsA antibodies. Fluorescently labelled IcsA passenger was also able to bind to host cell surfaces. Indirect probing with purified IcsA passenger protein recognised several host molecules through far Western blotting. Through screening of an IcsA 5 aa insertion library [24], the region responsible for adhesin activity was identified and characterised.
Materials and methods
Ethics statement
The anti-GST antibody and anti-IcsA antibody were produced under the National Health and Medical Research Council (NHMRC) Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, and was approved by the University of Adelaide Animal Ethics Committee.
Bacterial strains and tissue culture
The bacterial strains used in this study are listed in S1 Table. For adherence assays, bacterial strains were streaked onto Tryptic Soy Agar with 0.2% (w/v) Congo Red, and after incubation at 37°C overnight, red colonies were selected and incubated in Lysogeny broth (LB) overnight with appropriate antibiotics (tetracycline, 10 μg ml−1; kanamycin, 50 μg ml−1; chloramphenicol, 25 μg ml−1 and ampicillin, 100 μg ml−1). For all assays, overnight bacterial cultures were subcultured (1:20) in the presence or absence of 2.5 mM sodium deoxycholate and grown to a mid-exponential phase (OD600 reading of 0.6–0.8) before use.
HeLa cells were maintained and grown in minimal essential medium (MEM) supplemented with L-glutamine, 10% (v/v) fetal calf serum (FCS), and penicillin/streptomycin. Cell cultures were maintained at 37°C with 5% CO2 for growth. The day prior to the bacterial adherence assay and invasion assay, or for microscopy, HeLa cells were seeded at 4.5×105/well into 24-well plates or onto glass coverslips respectively. For plaque assays, HeLa cells were seeded into 6-well plates and were allowed to grow confluent.
Mutagenesis and DNA manipulation
S. flexneri 2a ΔipaD or ΔipaB strains were generated using the λ red mutagenesis method as described previously [25]. Briefly, primers (S2 Table) were designed to PCR amplify the kanamycin cassette flanked with 50 bp of the start and the end of the coding sequences of IpaD or IpaB. The fragments were then electroporated into WT S. flexneri 2457T or a ΔicsA knockout strain to generate ΔipaD/ΔipaB or ΔipaDΔicsA/ΔipaBΔicsA mutant strains. The kanamycin cassette was then eliminated by the introduction of pCP20 to avoid potential polar effects.
Site-directed mutagenesis was performed on pIcsA plasmid [24] using the QuikChange II® system (Agilent) as per the manufacturers protocol. The primers used are listed in S2 Table.
For alanine scanning of the amino region 138 to 148 in the IcsA passenger domain, codons of each amino acid were substituted with a codon of alanine and changed via inverse PCR with the primers listed in S2 Table.
The hyper-adherent mutant library was generated by transforming plasmids from the IcsA 5 aa insertion library [24] into S. flexneri 2a ΔipaDΔicsA via chemical transformation as described by Sambrook and Russell [26].
For IcsA production, the IcsA passenger sequence from amino acid 53 to 740 was amplified using primers MD80/81 (S2 Table) from pIcsA, and cloned into the pBADhisB vector (Invitrogen) between the XhoI and KpnI sites, resulting in pBADhisB::IcsA53-740. The vector was then optimised for purification by inverse PCR to replace the His×6 tag with a N-terminus fused His×12 tag, resulting in pMDBAD::IcsA53-740. For the IcsAΔ138–148 production, the coding sequence of amino acids 138 to 148 in the IcsA passenger domain was deleted via inverse PCR, resulting in pMDBAD::IcsA53-740(Δ138–148).
Protein purification and refolding
For IcsA passenger domain production, an overnight culture of E. coli TOP10 transformed with pMDBAD::IcsA53-740 was sub-cultured 1 in 1000 into auto-induction 2 L Terrific Broth medium [27] that contained a mixture of glucose and arabinose in the ratio of 0.1%:0.3% (w/v), and incubated at 37°C overnight. Cells were then harvested by centrifugation (10,000 ×g, 10 min), resuspended in 80 ml TBS [50 mM Tris, 150 mM NaCl, pH 7.0] and lysed using a cell disruptor (30 kpsi, Constant Systems Ltd) in the presence of two EDTA-free protease inhibitor tablets (Roche). Inclusion bodies (IBs) were recovered by centrifugation of the cell lysates (20,000 ×g, 10 min), and pre-cleaned by detergent wash [50 mM Tris, 1 M NaCl, 2% (v/v) Triton X-100, 4 mM DDM and 2% (w/v) DOC, pH 8.0] to exclude membrane fractions. IcsA passenger protein from the IBs was then solubilised in 50 ml protein solubilisation buffer [8 M urea, 50 mM NaCl, 50 mM Tris, 10 mM imidazole, pH 8] for 2 h, followed by centrifugation (185,000 ×g, 1 hr). Solubilised IcsA passenger protein was then loaded on a His-trap column, washed and eluted with increasing concentration of imidazole. IcsA passenger protein was then further purified through an HiLoad 16/600 Superdex 200pg column (GE Healthcare) and eluted fractions containing purified protein were confirmed by SDS-PAGE. IcsA passenger domain-containing fractions were then pooled and subjected to refolding.
Purified IcsA passenger protein was diluted 1:20 into base buffer [50 mM NaCl, 50 mM Tris, pH 8.0] with different screening ingredients or conditions including 10% (v/v) glycerol, 1.5 M NaCl, 1% (v/v) NP-40, 0.5 M urea, 10 mM DTT, 1% (w/v) glycine, 100 mM MgCl2 or pH 7.0. The mixtures were then incubated for 16 h at 4°C, and ultracentrifuged (185,000 ×g, 30 min) to separate the insoluble and soluble fractions. Samples of both insoluble and soluble fractions were compared by electrophoresis into a 12% polyacrylamide SDS-PAGE gel and subjected to Western transfer and Ponceau S staining. Conditions that yielded the least aggregation were then used, and the purified IcsA passenger protein was refolded by dialysing against optimised buffer [0.5 M urea, 10% (v/v) glycerol, 50 mM NaCl and 50 mM Tris-HCl pH 7.0] at room temperature for 48 h. Dialysed IcsA passenger protein was then ultracentrifuged (185,000 ×g, 1 h) and the resulting supernatant was quantified using the protein BCA assay (Thermo Fisher) and stored at -80°C. With this protocol a yield of IcsA of approximately 10 mg protein was obtained from a 2 L overnight culture.
Proteinase accessibility assay
Proteinase accessibility assay was performed as described by May and Morona [24] with modifications. Refolded IcsA passenger protein was incubated with Human Neutrophil Elastase (hNE, EPC Elastin Products) in dialysis buffer at the molecular ratio of 1000:1 at 37°C for 1.5 h. Aliquots were taken at different time points (0 min, 5 min, 10 min, 15 min, 30 min, 45 min, 60 min and 90 min) and immediately resuspended with an equal volume of SDS-PAGE sample buffer [29] followed by incubation at 100°C for 10 min. A sample of IcsA passenger protein was also heated at 65°C for 15 min, cooled to room temperature, and digested as above to serve as a control. Fractions taken from different time points were then analysed by SDS-PAGE and stained with Coomassie blue G250 (Sigma).
Fluorescent labelling
For protein labelling, refolded IcsA53-740 protein (that has three cysteine residues available for labelling with Dylight 594 (DL594) maleimide), mutant IcsA protein (IcsA53-740(Δ138–148)), or bovine serum albumin (BSA) protein (Sigma) were incubated with DL594 maleimide (Thermo Fisher) at the molecular ratio of 1:2 overnight at room temperature, and subsequently dialysed against dialysis buffer to remove excessive dye. Successfully labelled protein was analysed via SDS-PAGE and the fluorescence was confirmed using a ChemiDoc imaging system (BioRad).
IcsA immunofluorescent labelling on bacterial surfaces was performed as described previously [30]. Briefly, Shigella grown to an OD600 of 0.5 was collected and fixed in PBS containing 3.7% (v/v) formaldehyde and centrifuged onto poly-L-lysine-coated coverslips. Bacteria was then incubated with rabbit anti-IcsA antibody for 1 h, washed with PBS, and labelled with Alexa 488-conjugated donkey anti-rabbit antibody for another 1 h. Samples were then mounted with 20% (v/v) Mowiol 4–88 (Calbiochem), 4 mg ml−1 p-phenylenediamine, and imaged with an Olympus fluorescent microscope (IX-70).
SDS-PAGE and Western blotting
For SDS-PAGE, samples were resuspended in an equal volume of 2× SDS-PAGE sample buffer [29], and immediately heated at 100°C for 10 min. A total of 20 μl from each sample was then electrophoresed on Any kDTM gels (BioRad) or hand-cast 12% SDS acrylamide (BioRad) gels. For Western immunoblotting, samples were then transferred onto a nitrocellulose membrane, blocked with TBST [TBS, 0.05% (v/v) Tween-20] containing 5% (w/v) skim milk, and incubated with rabbit anti-IcsA antibody [28], rabbit anti-GST antibody (in house made), or mouse anti-His antibody (Genscript) for 4 h. The membrane was then washed with TBST and incubated with HRP-conjugated goat anti-mouse antibody (Biomediq DPC) or HRP-conjugated goat anti-rabbit antibody (Biomediq DPC) for 1 h. The membrane was then washed with TBS and incubated with Chemiluminescence Substrate (Sigma) for 5 min. Chemiluminescence was detected using a ChemiDoc imaging system (BioRad).
Confocal microscopy
To visualise the binding of IcsA to host cell surfaces, fluorescently labelled IcsA53-740 protein (2.8 μM), IcsA53-740(Δ138–148) protein (2.8 μM) or BSA protein (5 μM) were added onto confluent HeLa cell monolayers grown on coverslips in 24-well trays and incubated at 37°C with 5% CO2 for 15 min followed by washing with PBS. Monolayers were then fixed with 3.7% (v/v) formaldehyde in PBS, washed with PBS, incubated with 1% (v/v) Triton in PBS for 10 min, and then stained with AlexaFluor 488 phalloidin (Invitrogen) diluted to 1:100 in PBS containing 10% (v/v) FCS. Monolayers were then washed with PBS and DNA was stained using 10 μg ml−1 DAPI for 1 min, followed by another PBS wash. Coverslips were then mounted with 20% (v/v) Mowiol 4–88 (Calbiochem), 4 mg ml−1 p-phenylenediamine, and imaged with an Olympus confocal laser scanning microscope (FV3000).
Adherence, invasion and plaque formation assays
For whole cell adherence assays, Shigella grown to an OD600 of 0.4–0.6 were collected, washed with MEM, and inoculated to HeLa cell monolayers at the multiplicity of infection (MOI) of 100. Centrifugation (500 ×g, 5 min) was used as outlined in the results. After 15 min of incubation, HeLa cell monolayers were washed with PBS and lysed using PBS containing 0.1% (v/v) Triton X-100 at 37°C for 10 min. The remaining Shigella bacteria were enumerated by serial dilution plating onto LB agar.
For invasion assays, Shigella grown to an OD600 of 0.4–0.6 in the presence of DOC were used to infect HeLa cell monolayer at the MOI of 100. Gentamycin (40 μg ml-1) was added after 45 min post infection and HeLa monolayers were incubated for another 45 min before being lysed and treated as above.
Plaque formation was performed as described previously [30]. Briefly, HeLa cells grown to confluency in six-well trays were washed with PBS and Dulbecco’s modified Eagle’s medium (DMEM) sequentially before infection with of Shigella (1.25 ×105 cfu) grown to an OD600 of 0.5. At 90 min post infection, an overlay [DMEM, 5% (v/v) FCS, 20 μg ml-1 gentamycin, 0.5% (w/v) agarose] was added to each well. The second overlay containing 0.1% (w/v) Neutral Red was added at 48 h post infection and images of plaques were taken after another 2 h incubation.
Adherence blocking assays using purified IcsA or anti-IcsA antibody
For both adherence blocking assays, HeLa cells grown to confluence were washed with PBS, and replenished with culture medium devoid of antibiotics. For the IcsA adherence blocking assays, IcsA53-740 protein at different concentrations (2.5 μM, 1.25 μM, 250 nM and 25 nM) along with S. flexneri 2a strains were added onto monolayers at the MOI of 100:1. After an incubation of 15 min at 37°C with 5% CO2, samples were centrifuged (500 ×g, 5 min) and incubated for another 15 min as above.
For the antibody adherence blocking assays, bacteria were washed with PBS and replenished in the culture medium (as above) and incubated with either rabbit anti-IcsA pAbs (3.125 μg/ml and 0.3125 μg/ml) or rabbit pre-immune serum (concentration of IgG 100 μg/ml) for 15 min. Bacteria with antibodies were then added onto cell monolayers at the MOI of 100 and incubated for another 15 min at 37°C with 5% CO2. For both assays, unbound Shigella bacteria were washed three times with PBS, and monolayers were lysed using 0.1% (v/v) Triton X-100 at 37°C for 10 min. The remaining Shigella bacteria were enumerated by serial dilution plating onto LB agar.
Statistical analysis
The statistical analysis on Shigella adherence and invasion assays was performed using GraphPad Prism 8.0.0. Data were normalised against the relevant control and significance was calculated using either a student t test or one-way ANOVA followed by Dunnett’s multiple comparisons test against the control.
Protein lysates, cell fractionation and far Western blotting
HeLa cells grown to confluence on 100 mm dishes (approximately 8.8×108 cells) were recovered either by using a cell scraper or trypsin digestion, and washed with PBS followed by centrifugation (4,000 ×g, 5 min, 4°C). Pellets were lysed using RIPA buffer [25 mM Tris-HCl, 150 mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) deoxycholate, 0.1% (w/v) SDS, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml leupeptin] as described previously [31]. Lysates were then ultracentrifuged (185,000 ×g, 30 min, 4°C) and resuspended in the same volume of SDS-PAGE sample buffer, incubated at 95°C for 10 min, then electrophoresed into a 4–12% gradient SDS-PAGE gel (Thermo Fisher) and transferred onto a nitrocellulose membrane.
Cell fractionation was performed as described by Laarmann and Schmidt [32]. Briefly, HeLa cells were scraped from the 100 mm dishes into PBS containing 1 mM Pefabloc and 10 μg ml−1 leupeptin, and then sonicated on ice. The sonicated mix was then ultracentrifuged (108,000 ×g, 30 min, 4°C). The supernatant was isolated as the cytosolic fraction and the pellet was washed with PBS before resuspension in buffer containing 0.1 M Na2CO3/1 M NaCl (pH 11) and incubated on ice for 30 min. The extracted membrane lysate was then ultracentrifuged as above, resulting in a membrane associated fraction in the supernatant and the integral membrane fraction in the pellet. The pellet was solubilised in 2% (w/v) CHAPS in sonication buffer, and ultracentrifuged again, resulting in the detergent resistant integral membrane fraction in the pellet. All fractions were solubilised in SDS-PAGE sample buffer incubated at 95°C for 10 min, then electrophoresed into a 4–12% gradient SDS-PAGE gel (Thermo Fisher), and transferred onto a nitrocellulose membrane.
For far Western blotting, the membrane was blocked in 5% (w/v) skim milk in TBST [50 mM Tris, pH 7.0, 150 mM NaCl, 0.1% Tween 20] and incubated with 12.5 μg IcsA53-740 or IcsA53-740(Δ138–148) in TBST with 5% (w/v) skim milk overnight at 4°C. The membrane was then washed with TBS three times and the interaction between IcsA53-740 or IcsA53-740(Δ138–148) and host cell proteins was detected with the anti-IcsA antibody as above.
N-WASP pull down
For N-WASP pull down experiments, approximately 60 μg mini-N-WASP-GST protein purified as described previously [33] was mixed with either 12.5 μg IcsA53-740 or IcsA53-740(Δ138–148), and incubated with 200 μl glutathione SepharoseTM 4B (GE Healthcare) resin overnight at 4°C. IcsA53-740 and IcsA53-740(Δ138–148) were mixed with or without GST, incubated with glutathione SepharoseTM 4B (GE Healthcare) resin and served as controls. Resins were washed sequentially with PBS; PBS containing 1 mM DTT; PBS containing 0.1% (v/v) NP-40; and PBS for three times each. Protein was eluted in 50 μl PBS containing 20 mM reduced glutathione.
IcsA structure prediction
The structure of IcsA passenger was acquired using I-TASSER [34] and analysed using Chimera [35].
Results
Purification of IcsA passenger protein and refolding
In order to validate the role of IcsA in Shigella adherence in vitro, the IcsA passenger domain (53–740) without the previously described unstructured region (741–758) [15] was expressed from a pBAD vector with an N-terminal His×12 tag for purification (S1A Fig). IcsA53-740 was purified from urea solubilised inclusion bodies via nickel affinity purification. Fractions containing IcsA53-740 were pooled and further purified by size exclusion chromatography (S1B Fig) and refolded via dialysis. This purification strategy has significant advantages including high yields and reduced endogenous degradation of the autotransporter passenger domain, a type of domain family that is notoriously difficult to purify in a stable and soluble state.
Since human neutrophil elastase (hNE) has been reported to specifically target Shigella surface virulence factors [36] and has previously been used to assess the conformation and folding of IcsA [9], we conducted hNE digestions on the purified IcsA53-740 to assess the success of refolding. The purified IcsA53-740 showed several resistant fragments, with sizes of approximately 70 kDa, 60 kD, 40 kDa, 12 kDa and 5 kDa (S1D Fig), suggesting that the protein has a compact structure which is resistant to hNE proteolysis. Heat denaturation at 65°C for 5 min resulted in IcsA53-740 becoming susceptible to hNE, with complete digestion into fragments less than 15 kDa within the first 5 min (S1E Fig). In addition, the refolded IcsA53-740 was able to interact with mini-N-WASP protein (S2 Fig). Together, these data suggest that the purified IcsA53-740 was successfully refolded and was functional after purification from inclusion bodies.
Adherence of hyper-adhesion Shigella mutants is highly IcsA dependent
While previous data strongly indicated that IcsA has adhesin activity [9], this has not been directly demonstrated. We hypothesised that the passenger domain of IcsA directly binds specifically to host cell surface factors in a way that pre-treatment of host cells with purified IcsA53-740 would block the adherence of subsequently added S. flexneri. As expected, an ΔipaD mutant strain exhibited an increased adherence phenotype to HeLa cells compared to wild type S. flexneri (Fig 1A). This increase in adherence is dependent on the presence of IcsA because deletion of IcsA abolished the hyper-adherence (Fig 1A). More importantly, addition of the purified IcsA53-740, but not the dialysis buffer or BSA protein, was able to inhibit the adherence of the ΔipaD mutant to HeLa cells in a dose dependent manner (Fig 1A). This inhibition was also confirmed for a hyper-adherent ΔipaB mutant (S3 Fig). Moreover, these data also confirmed that the purified IcsA53-740 protein was folded in a functional conformation. To confirm that endogenous IcsA on the bacterial surface has a direct contribution to the adherence observed for the ΔipaD mutant, an adherence blocking assay using polyclonal anti-IcsA antibodies was also conducted (Fig 1B). It was found that pre-treatment of bacteria with anti-IcsA antibodies, but not the rabbit pre-immune serum, was able to significantly block the adherence of the ΔipaD mutant to host cells (Fig 1B). Collectively, these data confirmed a direct role of IcsA in the S. flexneri hyper-adherence activity exhibited by ΔipaD and ΔipaB mutants.
IcsA binds specifically to the host cells
Evidence was next generated to determine whether that the IcsA passenger domain binds specifically to host cell molecules as potential receptors for adherence. The purified IcsA53-740 was fluorescently labelled by reacting with DL594 maleimide (Fig 2A). BSA protein labelled with DL594 was used as a control (Fig 2A). Unlike the control BSA- DL594, IcsA53-740- DL594 was detected on the surface of the HeLa cells (Fig 2B). To investigate whether the interaction between IcsA53-740 and the HeLa cell surface was specified by a host cell displayed factor, trypsin treated, or untreated HeLa cells lysates were subjected to far Western blotting with IcsA53-740 protein (Fig 3A). Two trypsin sensitive molecules (~60 kDa and >200 kDa) were recognised by IcsA53-740 protein (Fig 3A). The anti-IcsA antibody showed no cross reaction to the HeLa cell lysate (Fig 3A). To further validate the cell surface location of these IcsA targets, HeLa cells were fractionated (Fig 3B), and subjected to far Western blotting with purified IcsA53-740. IcsA interacting components from integral membrane fractions (Fig 3B, lane 4) were detected and two of which were corresponding in size (>200 kDa and ~60 kDa) to the trypsin sensitive molecules from whole cell lysate (Fig 3A). Apart from these two molecules, we also detected bands at approximately 25 kDa and 20 kDa that interacted with IcsA53-740 (Fig 3B lane 4). A molecule at ~ 200 kDa was detected across the all fractions (Fig 3B, lane 1, 2 & 4). These data suggest that the interactions between the IcsA53-740 passenger domain and the host cell surface is specific and complex.
IcsA amino acid region 138–148 is required for adhesion
To identify functional regions required in adhesin activity, we utilised our previously generated plasmid collection that express IcsA mutants harbouring 5 amino acid insertions across the passenger domain [24] to screen for defects in S. flexneri adherence. These plasmids were introduced into S. flexneri ΔipaDΔicsA and transformants were used in adherence assays with HeLa cells. In a preliminary experiment attempting to repeat the result of Brotcke-Zumsteg, Goosmann, et al. [9], the IcsAi148 mutant but not the IcsAi386 mutant had an adherence defect (S4A Fig). The screening was then focused on the N-terminus of IcsA passenger domain and three sites (i138, i140 and i148) were found to result in mutated IcsA protein having significant defect in adherence activity (S4B Fig). To further investigate this region (138–148), the amino acids from 138 to 148 were each substituted for alanine and the resulting mutants were screened via HeLa adherence assays (S4C Fig). However, none of these mutants conferred a significant defect in adherence indicating that a larger region, rather than individual residues, drives host receptor interactions. Subsequently, the adjacent amino acids to the i138, i140 and i148 insertion sites (138 and 139, 140 and 141, and 148 and 149 respectively) were randomly substituted and screened for the defects in adherence. Two IcsA mutants (IcsAI138P and IcsAQ148C/G149N) were found to cause complete loss of IcsA adherence function (Fig 4A). A deletion spanning this region (IcsAΔ138–148), was likewise defective in adherence (Fig 4B). To rule out any confounding effects caused by centrifugation, adherence assays were also performed with passive settling of bacteria (Fig 4C). Compared to the point mutants IcsAI138P and IcsAQ148C/G149N, the deletion mutant (IcsAΔ138–148) was found to have the greatest defect in adherence (Fig 4C).
The adherence functional region 138 to 148 is within the glycine repeat region [24], thus deletion of this region might affect IcsA biogenesis and/or its ABM function. To test this, the expression, polar localisation, and ABM function of IcsAΔ138–148 were confirmed by Western blotting (S5A Fig), immunofluorescent staining (S5B Fig), and plaque formation (S5C Fig) respectively. There was no difference in IcsA expression level, its surface localisation, and the size of plaques formed, between IcsA and IcsAΔ138–148. This rules out any major defects in IcsA biogenesis and ABM function for this mutant.
To validate that IcsAΔ138–148 has a defect in adherence in vitro, IcsA53-740(Δ138–148) was expressed, purified, and refolded in an equivalent manner to IcsA53-740. Refolded IcsA53-740(Δ138–148) was able to interact with mini-N-WASP protein in vitro (S2 Fig), confirming that the region 138–148 is not essential for IcsA’s ABM function, and that purified IcsA53-740(Δ138–148) protein was functional. However, relative to IcsA53-740, IcsA53-740(Δ138–148) was unable to block the adherence of S. flexneri ΔipaD (Fig 5A). Moreover, in far Western blotting of HeLa cell lysates, unlike IcsA53-740, IcsA53-740(Δ138–148) had greatly reduced interaction with host molecules (Fig 5B), given that the deletion of 138–148 did not affect the recognition via anti-IcsA antibody (S2 Fig). Fluorescently labelled IcsA53-740(Δ138–148) (Fig 6A) was prepared and used to label HeLa cells, but no staining was detected (Fig 6C). These data further supporting the notion that residues 138 to 148 affect IcsA’s adhesin function.
In the human gut, Shigella virulence is activated by, among other stimuli, bile salt components such as DOC [37].The impact of the aa 138–148 region on DOC induced hyper-adherence was investigated. As expected, DOC at the physiological concentration 2.5 mM was able to enhance the adherence of Shigella significantly (Fig 7A). However, the IcsAΔ138–148 mutant displayed a significant defect in the DOC enhanced adherence (Fig 7A), which again confirmed that the region from 138–148 is required for the IcsA-mediated adherence. Moreover, invasion of HeLa cells by S. flexneri ΔicsA complemented with IcsAΔ138–148 to HeLa cells was also significantly attenuated (Fig 7B), indicating that the IcsA-mediated adherence is required for Shigella invasion.
Discussion
In this work we have generated evidence that IcsA directly contributes to adherence of Shigella species to host cells. We were able to block the hyper-adherence phenotype of S. flexneri ΔipaD strains using either purified IcsA53-740 passenger domain or anti-IcsA antibody. Purified IcsA53-740 was able to bind host cell surfaces and recognised a multitude of host cell molecules. In addition, IcsA residues 138–148 were shown to be critical for adhesin function and purified IcsA53-740(Δ138–148) could no longer block Shigella adherence to host cells and was unable to recognise host cell molecules via far Western immunoblotting.
IcsA does not have detectable adherence activity in wild-type S. flexneri unless exposed to environmental stimuli (such as DOC) [37], or via activation of the T3SS [9]. IcsA adherence activity is strongly associated to a conformational change as detected by proteinase accessibility [9]. Nevertheless, in E. coli, heterogeneously expressed IcsA can promote bacterial adherence to host cells [9], presumably because the conformation, stimuli, folding, or modification of IcsA is different to that of the S. flexneri. Indeed, through hNE digestion analysis on our refolded IcsA53-740, we detected a resistant fragment of ~40 kD similarly to that reported previously for the hNE digestion of IcsA on intact S. flexneri bacteria [9], where a fragment around 40 kDa was more resistant to degradation by hNE in those strains with increased IcsA-mediated adherence. It is plausible that in Shigella, IcsA’s function in adherence is carefully downregulated by some mechanism governed by the T3SS before it encounters an environmental cue, such as DOC, whereas in E. coli, lack of such a regulating system allows IcsA to exert its adherence function constitutively.
The purified and refolded IcsA53-740 passenger domain retains its activity as a Shigella adhesin. Due to this, pre-incubation of the HeLa cells with purified IcsA53-740protein blocks the adherence of S. flexneri ΔipaD and ΔipaB strain. The minimum IcsA concentration in our experiments showing significant adherence blocking was 1.25 μM, which is approximately 10,000 times to the IcsA molecules expressed per input bacteria, assuming that each bacterium expresses approximately 4,000 IcsA molecules on the surface [38]. This is likely because purified IcsA53-740 must bind to many host cell receptors to block adherence. Indeed, comparable concentrations of antigens were also used to block virus entry [39] and bacteria adherence [40] to host cells. This is also supported by both the fluorescent labelling of HeLa cell surface and the far Western immunoblotting with purified IcsA53-740, indicating a specific and complex interaction between IcsA and host cells. It was not surprising that IcsA53-740 recognised other molecules from both cytosolic and membrane associated fractions, as IcsA is known to interact with cytosolic molecules responsible for actin based motility [19] and is recognised by host cell autophagic systems [41]. In our antibody blocking assay, the anti-IcsA antibody at 3.125 μg/ml blocked the Shigella adherence significantly, which is comparable to the concentrations of antibodies used in other studies [42–44]. Given that our data support a model where IcsA may recognise multiple receptors on host cells, and that anti-IcsA antibodies were able to neutralise Shigella adherence in vitro, this strongly suggests that the IcsA passenger domain has excellent vaccine potential.
The previous study using our IcsA insertion library found insertions at sites 148 and 386 affected IcsA-mediated Shigella adherence [9]. However, in the present study i138, i140, and i148, but not i386, were found to result in decreased IcsA-mediated adherence. The discrepancy at the site 386 is possibly due to the differences in the screening system. In the previous study [9], IcsA mutants with normal ABM function and defects in DOC-enhanced Shigella invasion were selected, whereas in this study, the adherence region was screened directly by assessing the adherence of Shigella IcsA insertion mutants to HeLa cells. While alanine scanning mutagenesis of the region 138–148 showed no significant defect in adherence, it is likely that the entire region 138–148 is required for multiple contacts between IcsA and host cell receptors such that the overall interface stability between IcsA and receptor cannot be significantly reduced by any single alanine substitution. Nevertheless, site-directed mutagenesis on the IcsAi-adjacent amino acids revealed substitution mutants (I138P and Q148C/G149N) that resulted in significant defects in adherence. Moreover, deletion of the entire region (138–148) in the IcsA passenger domain also reproduced the defect of the 5aa insertions, and was much more severe compared to the double mutants.
We speculate that this 138–148 IcsA region is involved in host cell receptor binding events. Indeed, in a predicted IcsA passenger structure (S6 Fig), the predicted β-rung harbouring aa 138–148 is smaller than the adjacent β-helixes and generates a groove in the IcsA passenger domain that might function as a putative receptor binding cleft. The Q148C found next to another cysteine (C130) in space located on the adjacent β-strand in the β-helix potentially allows the formation of a disulfide bond that might obstruct this binding cleft. Furthermore, purified mutant IcsA53-740(Δ138–148) passenger domain was unable to block adherence and showed reduced interactions to host cell components further supporting our speculations that this region might be a binding cleft for host receptors. Even DOC-stimulated hyper-adherence of S. flexneri expressing mutant IcsA (IcsAΔ138–148) consistently showed a defect in adherence and host cell invasion. IcsA has established functional roles in binding of host cell cytosolic factors to nucleate ABM, and the IcsA passenger domain can also accommodate further functions in adhesion via a specific binding region. Therefore, IcsA is a truly multifunctional virulence factor providing an avenue for Shigella to quickly respond to the pathogenic niche for adhesion, invasion, and spreading [45].
Supporting information
S1 Fig [s]
Expression, purification and refolding of the IcsA passenger protein.
S2 Fig [upper]
Purified IcsA protein was able to interact with mini-N-WASP.
S3 Fig [icsa1]
Inhibition of the IcsA-mediated adherence of with IcsA protein.
S4 Fig [tif]
Screening of the IcsA mutants via adherence assays.
S5 Fig [tif]
The region 138–148 does not affect IcsA’s expression, localization and ABM function.
S6 Fig [tif]
Structural analysis of the amino group substitution sites in the IcsA passenger domain.
S1 Raw Images [pdf]
Raw image files of Western immunoblotting and SDS-PAGE gels in the manuscript.
S1 Table [pdf]
Strains and plasmids.
S2 Table [pdf]
Oligonucleotides.
Zdroje
1. Speelman P, Kabir I, Islam M. Distribution and spread of colonic lesions in shigellosis: a colonoscopic study. J Infect Dis. 1984;150(6):899–903. Epub 1984/12/01. doi: 10.1093/infdis/150.6.899 6501931.
2. Good RC, May BD, Kawatomari T. Enteric pathogens in monkeys. J Bacteriol. 1969;97(3):1048–55. Epub 1969/03/01. 4180466; PubMed Central PMCID: PMC249813.
3. Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AKM. Shigellosis. Lancet. 2018;391(10122):801–12. Epub 2017/12/20. doi: 10.1016/S0140-6736(17)33296-8 29254859.
4. Kozyreva VK, Jospin G, Greninger AL, Watt JP, Eisen JA, Chaturvedi V. Recent outbreaks of shigellosis in California caused by two distinct populations of Shigella sonnei with either increased virulence or fluoroquinolone resistance. Msphere. 2016;1(6). Epub 2016/12/29. doi: 10.1128/mSphere.00344-16 28028547; PubMed Central PMCID: PMC5177732.
5. Anand BS, Malhotra V, Bhattacharya SK, Datta P, Datta D, Sen D, et al. Rectal histology in acute bacillary dysentery. Gastroenterology. 1986;90(3):654–60. Epub 1986/03/01. doi: 10.1016/0016-5085(86)91120-0 3510937.
6. Wassef JS, Keren DF, Mailloux JL. Role of M cells in initial antigen uptake and in ulcer formation in the rabbit intestinal loop model of shigellosis. Infect Immun. 1989;57(3):858–63. Epub 1989/03/01. 2645214; PubMed Central PMCID: PMC313189.
7. Ranganathan S, Doucet M, Grassel CL, Delaine-Elias B, Zachos NC, Barry EM. Evaluating Shigella flexneri pathogenesis in the human enteroid model. Infect Immun. 2019;87(4). Epub 2019/01/16. doi: 10.1128/IAI.00740-18 30642900; PubMed Central PMCID: PMC6434113.
8. Arena ET, Campbell-Valois FX, Tinevez JY, Nigro G, Sachse M, Moya-Nilges M, et al. Bioimage analysis of Shigella infection reveals targeting of colonic crypts. Proc Natl Acad Sci U S A. 2015;112(25):E3282–90. Epub 2015/06/10. doi: 10.1073/pnas.1509091112 26056271; PubMed Central PMCID: PMC4485126.
9. Brotcke-Zumsteg A, Goosmann C, Brinkmann V, Morona R, Zychlinsky A. IcsA is a Shigella flexneri adhesin regulated by the type III secretion system and required for pathogenesis. Cell Host Microbe. 2014;15(4):435–45. doi: 10.1016/j.chom.2014.03.001 24721572
10. Emsley P, Charles IG, Fairweather NF, Isaacs NW. Structure of Bordetella pertussis virulence factor P.69 pertactin. Nature. 1996;381(6577):90–2. Epub 1996/05/02. doi: 10.1038/381090a0 8609998.
11. Charbonneau ME, Janvore J, Mourez M. Autoprocessing of the Escherichia coli AIDA-I autotransporter: a new mechanism involving acidic residues in the junction region. J Biol Chem. 2009;284(25):17340–51. Epub 2009/04/29. doi: 10.1074/jbc.M109.010108 19398552; PubMed Central PMCID: PMC2719369.
12. Heras B, Totsika M, Peters KM, Paxman JJ, Gee CL, Jarrott RJ, et al. The antigen 43 structure reveals a molecular Velcro-like mechanism of autotransporter-mediated bacterial clumping. Proc Natl Acad Sci U S A. 2014;111(1):457–62. Epub 2013/12/18. doi: 10.1073/pnas.1311592111 24335802; PubMed Central PMCID: PMC3890832.
13. Doyle MT, Tran EN, Morona R. The passenger-associated transport repeat promotes virulence factor secretion efficiency and delineates a distinct autotransporter subtype. Mol Microbiol. 2015;97(2):315–29. Epub 2015/04/15. doi: 10.1111/mmi.13027 25869731.
14. Doyle MT, Grabowicz M, Morona R. A small conserved motif supports polarity augmentation of Shigella flexneri IcsA. Microbiology. 2015;161(11):2087–97. Epub 2015/09/01. doi: 10.1099/mic.0.000165 26315462.
15. Kuhnel K, Diezmann D. Crystal structure of the autochaperone region from the Shigella flexneri autotransporter IcsA. J Bacteriol. 2011;193(8):2042–5. Epub 2011/02/22. doi: 10.1128/JB.00790-10 21335457; PubMed Central PMCID: PMC3133035.
16. Leupold S, Busing P, Mas PJ, Hart DJ, Scrima A. Structural insights into the architecture of the Shigella flexneri virulence factor IcsA/VirG and motifs involved in polar distribution and secretion. J Struct Biol. 2017;198(1):19–27. Epub 2017/03/08. doi: 10.1016/j.jsb.2017.03.003 28268178.
17. Goldberg MB, Barzu O, Parsot C, Sansonetti PJ. Unipolar localization and ATPase activity of IcsA, a Shigella flexneri protein involved in intracellular movement. Infect Agents Dis. 1993;2(4):210–1. Epub 1993/08/01. 8173795.
18. Goldberg MB, Theriot JA. Shigella flexneri surface protein IcsA is sufficient to direct actin-based motility. Proc Natl Acad Sci U S A. 1995;92(14):6572–6. Epub 1995/07/03. doi: 10.1073/pnas.92.14.6572 7604035; PubMed Central PMCID: PMC41560.
19. Teh MY, Morona R. Identification of Shigella flexneri IcsA residues affecting interaction with N-WASP, and evidence for IcsA-IcsA co-operative interaction. PloS one. 2013;8(2):e55152. Epub 2013/02/14. doi: 10.1371/journal.pone.0055152 23405119; PubMed Central PMCID: PMC3566212.
20. Suzuki T, Sasakawa C. N-WASP is an important protein for the actin-based motility of Shigella flexneri in the infected epithelial cells. Jpn J Med Sci Biol. 1998;51 Suppl:S63–8. Epub 1999/04/22. doi: 10.7883/yoken1952.51.supplement1_s63 10211437.
21. Suzuki T, Mimuro H, Suetsugu S, Miki H, Takenawa T, Sasakawa C. Neural Wiskott-Aldrich syndrome protein (N-WASP) is the specific ligand for Shigella VirG among the WASP family and determines the host cell type allowing actin-based spreading. Cell Microbiol. 2002;4(4):223–33. Epub 2002/04/16. doi: 10.1046/j.1462-5822.2002.00185.x 11952639.
22. Egile C, Loisel TP, Laurent V, Li R, Pantaloni D, Sansonetti PJ, et al. Activation of the CDC42 effector N-WASP by the Shigella flexneri IcsA protein promotes actin nucleation by Arp2/3 complex and bacterial actin-based motility. J Cell Biol. 1999;146(6):1319–32. Epub 1999/09/24. doi: 10.1083/jcb.146.6.1319 10491394; PubMed Central PMCID: PMC2156126.
23. Koseoglu VK, Hall CP, Rodriguez-Lopez EM, Agaisse H. The autotransporter IcsA promotes Shigella flexneri biofilm formation in the presence of bile salts. Infect Immun. 2019;87(7):e00861–18. Epub 2019/04/17. doi: 10.1128/IAI.00861-18 30988059; PubMed Central PMCID: PMC6589070.
24. May KL, Morona R. Mutagenesis of the Shigella flexneri autotransporter IcsA reveals novel functional regions involved in IcsA biogenesis and recruitment of host neural Wiscott-Aldrich syndrome protein. J Bacteriol. 2008;190(13):4666–76. Epub 2008/05/06. doi: 10.1128/JB.00093-08 18456802; PubMed Central PMCID: PMC2446779.
25. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. 2000;97(12):6640–5. Epub 2000/06/01. doi: 10.1073/pnas.120163297 10829079; PubMed Central PMCID: PMC18686.
26. Sambrook J, Russell DW. The inoue method for preparation and transformation of competent E. Coli: "ultra-competent" cells. CSH Protoc. 2006;2006(1). Epub 2006/01/01. doi: 10.1101/pdb.prot3944 22485385.
27. Tartoff KD, Hobbs CA. Improved media for growing plasmid and cosmid clones. Bethesda Research Laboratories Focus. 1987;9(12).
28. Van den Bosch L, Manning PA, Morona R. Regulation of O-antigen chain length is required for Shigella flexneri virulence. Mol Microbiol. 1997;23(4):765–75. Epub 1997/02/01. doi: 10.1046/j.1365-2958.1997.2541625.x 9157247.
29. Lugtenberg B, Meijers J, Peters R, van der Hoek P, van Alphen L. Electrophoretic resolution of the ‘major outer membrane protein’ of Escherichia coli K12 into four bands. FEBS Lett. 1975;58(1–2):254–8. doi: 10.1016/0014-5793(75)80272-9
30. May KL, Grabowicz M, Polyak SW, Morona R. Self-association of the Shigella flexneri IcsA autotransporter protein. Microbiology. 2012;158(Pt 7):1874–83. Epub 2012/04/21. doi: 10.1099/mic.0.056465-0 22516224.
31. Suzuki T, Miki H, Takenawa T, Sasakawa C. Neural Wiskott-Aldrich syndrome protein is implicated in the actin-based motility of Shigella flexneri. The EMBO journal. 1998;17(10):2767–76. Epub 1998/06/10. doi: 10.1093/emboj/17.10.2767 9582270; PubMed Central PMCID: PMC1170617.
32. Laarmann S, Schmidt MA. The Escherichia coli AIDA autotransporter adhesin recognizes an integral membrane glycoprotein as receptor. Microbiology. 2003;149(Pt 7):1871–82. Epub 2003/07/12. doi: 10.1099/mic.0.26264-0 12855738.
33. Papayannopoulos V, Co C, Prehoda KE, Snapper S, Taunton J, Lim WA. A polybasic motif allows N-WASP to act as a sensor of PIP(2) density. Mol Cell. 2005;17(2):181–91. Epub 2005/01/25. doi: 10.1016/j.molcel.2004.11.054 15664188.
34. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5(4):725–38. Epub 2010/04/03. doi: 10.1038/nprot.2010.5 20360767; PubMed Central PMCID: PMC2849174.
35. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12. Epub 2004/07/21. doi: 10.1002/jcc.20084 15264254.
36. Weinrauch Y, Drujan D, Shapiro SD, Weiss J, Zychlinsky A. Neutrophil elastase targets virulence factors of enterobacteria. Nature. 2002;417(6884):91–4. Epub 2002/05/23. doi: 10.1038/417091a 12018205.
37. Pope LM, Reed KE, Payne SM. Increased protein secretion and adherence to HeLa cells by Shigella spp. following growth in the presence of bile salts. Infect Immun. 1995;63(9):3642–8. Epub 1995/09/01. 7642302; PubMed Central PMCID: PMC173505.
38. Magdalena J, Goldberg MB. Quantification of Shigella IcsA required for bacterial actin polymerization. Cell Motil Cytoskel. 2002;51(4):187–96. Epub 2002/04/27. doi: 10.1002/cm.10024 11977093.
39. Tiwari V, Liu J, Valyi-Nagy T, Shukla D. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. J Biol Chem. 2011;286(28):25406–15. Epub 2011/05/21. doi: 10.1074/jbc.M110.201103 21596749; PubMed Central PMCID: PMC3137111.
40. Rose L, Shivshankar P, Hinojosa E, Rodriguez A, Sanchez CJ, Orihuela CJ. Antibodies against PsrP, a novel Streptococcus pneumoniae adhesin, block adhesion and protect mice against pneumococcal challenge. J Infect Dis. 2008;198(3):375–83. Epub 2008/05/30. doi: 10.1086/589775 18507531.
41. Ogawa M, Yoshimori T, Suzuki T, Sagara H, Mizushima N, Sasakawa C. Escape of intracellular Shigella from autophagy. Science. 2005;307(5710):727–31. Epub 2004/12/04. doi: 10.1126/science.1106036 15576571.
42. Zhao WD, Liu DX, Wei JY, Miao ZW, Zhang K, Su ZK, et al. Caspr1 is a host receptor for meningitis-causing Escherichia coli. Nat Commun. 2018;9(1):2296. Epub 2018/06/14. doi: 10.1038/s41467-018-04637-3 29895952; PubMed Central PMCID: PMC5997682.
43. Perez-Zsolt D, Erkizia I, Pino M, Garcia-Gallo M, Martin MT, Benet S, et al. Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry. Nat Microbiol. 2019;4(9):1558–70. Epub 2019/06/05. doi: 10.1038/s41564-019-0453-2 31160823.
44. Amerighi F, Valeri M, Donnarumma D, Maccari S, Moschioni M, Taddei A, et al. Identification of a monoclonal antibody against pneumococcal pilus 1 ancillary protein impairing bacterial adhesion to human epithelial cells. J Infect Dis. 2016;213(4):516–22. Epub 2015/09/25. doi: 10.1093/infdis/jiv461 26401026.
45. Koseoglu VK, Agaisse H. Evolutionary perspectives on the moonlighting functions of bacterial factors that support actin-based motility. MBio. 2019;10(4). Epub 2019/08/29. doi: 10.1128/mBio.01520-19 31455648; PubMed Central PMCID: PMC6712393.
Článek vyšel v časopise
PLOS One
2020 Číslo 1
- Řekněte mi, co jíte, a já vám řeknu, jaká je úroveň vaší kognice
- Původní český test ALBA pro odhalení mírných kognitivních deficitů získal certifikaci MZ ČR
- Duševní onemocnění se u teenagerů přenáší v rámci školní třídy
- Od kostiček k lidské kůži. Jak si postavit 3D biotiskárnu?
- Prof. Libor Grubhoffer: Nová varianta mpox je příležitostí pokročit v poznání původce varioly
Nejčtenější v tomto čísle
- Severity of misophonia symptoms is associated with worse cognitive control when exposed to misophonia trigger sounds
- Chemical analysis of snus products from the United States and northern Europe
- Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice
- Effect of Lactobacillus acidophilus D2/CSL (CECT 4529) supplementation in drinking water on chicken crop and caeca microbiome